首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

【24h】

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

机译：I阶段研究检查点激酶1抑制剂GDC-0575与令人难抑使实体瘤患者的吉西他滨组合

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2018年第5期|共8页
作者
AItaliano; J RInfante; G IShapiro; K NMoore; P MLoRusso; EHamilton; SCousin; MToulmonde; SPostel-Vinay; STolaney; E MBlackwood; SMahrus; F VPeale; XLu; AMoein; JEpler; KDuPree; MTagen; E RMurray; J LSchutzman; J OLauchle; AHollebecque; J -CSoria;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors [J] . AItaliano, J RInfante, G IShapiro, Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第5期

机译：I阶段研究检查点激酶1抑制剂GDC-0575与令人难抑使实体瘤患者的吉西他滨组合
2. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. [J] . Edward Sausville, Patricia Lorusso, Michael Carducci, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：在美国晚期实体瘤患者中，检查点激酶抑制剂AZD7762与吉西他滨联合进行I期剂量递增研究。
3. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. [J] . Edward Sausville, Patricia Lorusso, Michael Carducci, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：AZD7762，Checkpoint激酶抑制剂的I相剂量 - 升级研究，与美国晚期实体瘤患者的吉西他滨组合。
4. SHORT-TERM TUMOR RESPONSE TO TYROSINE KINASE INHIBITORS VERSUS LONG-TERM SURVIVAL IN MAST CELL TUMORS: FOLLOW-UP DATA FROM A PIVOTAL FIELD STUDY WITH MASITINIB [C] . Olivier Hermine Annual Conference of the Veterinary Cancer Society . 2009

机译：短期肿瘤对酪氨酸激酶抑制剂的反应与肥大细胞肿瘤的长期存活：来自Masitinib的关键田间研究的后续数据
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase I dose-escalation study of AZD7762 a checkpoint kinase inhibitor in combination with gemcitabine in US patients with advanced solid tumors [O] . Edward Sausville, Patricia LoRusso, Michael Carducci, -1

机译：在美国晚期实体瘤患者中检查点激酶抑制剂AZD7762与吉西他滨联用的I期剂量递增研究
7. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors [O] . Edward Sausville, Patricia LoRusso, Michael Carducci, 2014

机译：AZD7762，Checkpoint激酶抑制剂的AZD7762的阶段升级研究与美国高级实体瘤患者组合的吉西他滨组合

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号